Clinical Trial Update: First in Human, Dose Escalation Study of AN4005 [Phase 1]

View source ↗

Summary

First-in-human, dose-escalation study of AN4005 in patients with advanced solid tumors and advanced lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• AN4005

Snippet

Sponsor: Adlai Nortye Biopharma Co., Ltd. | Conditions: Advanced Solid Tumor, Advanced Lymphoma | Phase 1 | Status: RECRUITING